Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Clinical trial NCT05911295 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05911295
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-22
- Primary completion
- 2027-01-29
- Enrollment
- 412
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.